Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD and Food Effect Study of RV299
NCT06033612Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RV299 in respiratory syncytial virus infection (RSV) (3 arms), sponsored by Pfizer. Primary endpoints: Number of participants with treatment-emergent adverse events, Proportion of participants with clinically significant shifts in laboratory values and 6 more. Started Nov 2021; status: completed.
02
Drugs
RV299
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06033612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06033612.